Canaccord Genuity and Stifel the joint bookrunning managers
By Devika Patel
Knoxville, Tenn., June 4 - LeMaitre Vascular, Inc. said the underwriters for its public offering of stock opted to exercise the deal's $1.5 million greenshoe in full for total proceeds of $11.51 million. The deal was announced on May 29 and priced for $10.01 million with the greenshoe on May 30.
The company sold 1,644,500 common shares at $7.00 apiece. The price per share is an 8.26% discount to the May 29 closing share price of $7.63. Of the shares, 214,500 were part of the fully exercised greenshoe.
Canaccord Genuity and Stifel were the joint bookrunners.
Proceeds will be used for general corporate purposes, including product development, working capital and capital expenditures.
The Burlington, Mass., company develops medical devices and implants for the treatment of peripheral vascular disease.
| Issuer: | LeMaitre Vascular, Inc.
|
| Issue: | Common shares
|
| Amount: | $11,511,500 (including $1,501,500 greenshoe)
|
| Shares: | 1,644,500
|
| Price: | $7.00
|
| Warrants: | No
|
| Bookrunners: | Canaccord Genuity and Stifel
|
| Co-managers: | Roth Capital Partners, Barrington Research Associates, Benchmark Co. and Brean Capital
|
| Announcement date: | May 29
|
| Pricing date: | May 30
|
| Settlement date: | June 4
|
| Stock symbol: | Nasdaq: LMAT
|
| Stock price: | $7.63 at close May 29
|
| Market capitalization: | $113.35 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
